Send PM
Followers 995
Posts 190839
Boards Moderated 1
Alias Born 06/19/2009

Re: None

Tuesday, 06/07/2016 10:44:33 AM

Tuesday, June 07, 2016 10:44:33 AM

Post# of 1175
OXGN All in one DD: P2 Study of CA4P in Recurrent Ovarian Cancer already Met Primary Endpoint of Improvement.

At $10 cap will be around $200m.still reasonable relating market potential,imo. The FDA already granted a Fast Track status to CA4P. Very solid balance sheet,trading way under Net Assets.

OXGN to hit two birds with one stone,awesome: (shareholders wouldn't have voted to no R/S if weren't pretty sure it wouldn't be necessary imo,Catalyst this month).

June 2016 Catalysts:this

Assets/debt ratio=12 very solid(even rare),Net Assets(total assets minus total liabilities)= $22m. currently trading under $17m cap.

Many upcoming Catalysts:

Latest Presentation:

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.